Programa Cero Invex

Programa provides you with a complete suite of indispensable collaboration tools and templates to elevate your interior design projects. Catering to experienced professionals in the design and architecture industry, Programa’s user-friendly platform streamlines project management, optimizes efficiency, and fosters collaboration among team ...

Programa Cero Invex 1

Learn about Programa's simple pricing model or get started today with your free trial. No credit card required.

Programa Cero Invex 2

Explore all of Programa’s tools—Schedules, Dashboards, Web Clipper, and more—built to simplify every stage of your design workflow.

Programa Cero Invex 3

Made for designers and integrated with your daily workflows, Programa is the best project management software for interior designers and architects.

Programa Cero Invex 4

Editorial Made with Programa Blog Success stories from our users Studio Bosko: Zander Rooftop For Studio Bosko, Programa replaced spreadsheets, scattered folders, and improvised communication with a single workspace.

Programa is a new integrated way of running your design business or brand. With project, process and product brought together on one platform, you’re free to create and do business on the same digital page. Join thousands of architects, designers and brands helping us propel our industry forward.

Find the latest CERo Therapeutics Holdings, Inc. (CERO) stock quote, history, news and other vital information to help you with your stock trading and investing.

Programa Cero Invex 7

We are advancing a CER T-cell platform that potentially offers novel approaches for the treatment of both hematologic malignancies and solid tumors. Therapeutic Potential of our Platform. © 2026 CERo Therapeutics, Inc. All Rights Reserved.

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors.